HR Execs on the Move


 
Elan is a biotechnology company, headquartered in Ireland, committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world.
  • Number of Employees: 250-1000
  • Annual Revenue: > $1 Billion
  • www.elan.com
  • 300 Technology Sq Third Floor
    Cambridge, MA USA 02139
  • Phone: 617.715.8280

Executives

Name Title Contact Details

Similar Companies

CHUL Research Center

CHUL Research Center is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Copernicus

Copernicus is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.

CK Life Sciences Int'l. Inc

CK Life Sciences Int'l. Inc is a Kirkland, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Triplet Therapeutics

Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington`s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.